The Handoff: Your Week in Neurology News - 1/19/17

Share this content:

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, the pharmaceutical industry, and the overall state of health care as it affects neurologists.

— UCB Pharma has filed a supplemental NDA for its drug brivaracetam for indication as a monotherapy for the treatment of partial-onset seizures in patients aged 16 years and older. The drug is currently approved as adjunctive treatment. 

— Sarepta reported $5.4 million in sales of its Duchenne muscular dystrophy drug eteplirsen in the December quarter despite a hefty price tag. 

— Biogen has settled a patent dispute with Danish biotech company Forward Pharma A/S over a key ingredient in Tecfidera, its top multiple sclerosis drug. 

— Are pharmacists the key to managing the growing Alzheimer's dementia population? 

— Patient advocacy groups might not be the purists you expect, a feature from Stat News claims. The groups, which have played very active roles in new drug approvals, are increasingly supported by industry. 

— Biogen and Siemens are teaming up to develop more quantitative metrics for MRI in multiple sclerosis, with hopes that it will help better define patient prognosis and response to therapy. 

— The NFL and Texas Medical Center are calling for submissions for their 1st & Future sports tech competition. Pitches should focus on 1 of 3 categories: coach-player communication, athlete training, or athlete protection, and winners will receive a $50,000 check, acceptance into TMC's accelerator, and Super Bowl tickets, of course. 

— Will "mini-brains" replace the animal model in neurological research? A group from Johns Hopkins trying to commercialize them hope so. 

— Canadian police are warning the medical community to be on the lookout for fake medical or research conferences after 2 fake neurological conferences were caught advertising a fake event. 

Stat News went inside a DEA drug lab, where chemists are busy analyzing compounds to try and identify the newest, most potent opioids. Watch the video below to learn more about the risky operation. 

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus